Arseus NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics (Premium)
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Arseus NV Announces Fagron's Acquisitions in Brazil, Colombia and Denmark and Partnership with NxGen Pharmaceuticals Regarding Fagron Australia Site
Arseus NV announced Fagron's acquisitions in Brazil, Colombia and Denmark. In Colombia, Fagron finalized the acquisition of Orbus Pharma. It also acquired four compounding pharmacies from Quifarma. The five compounding pharmacies are located in Bogota, Medellin and Cali and are specialized in the preparation of tailor-made medication. After the acquisitions of DEG (Fagron Brazil) in 2010 and Pharma Nostra in 2011, Fagron further acquired Florien. In Denmark, Fagron finalized the acquisition of Copenhagen-based ApodanNordic PharmaPackaging A/S. Established in 1962, ApodanNordic PharmaPackaging specializes in the development and sale of packaging materials for pharmaceutical compounding to pharmacies and hospitals. Additionally the Company announced that Fagron has entered into a partnership in Australia with NxGen Pharmaceuticals, resulting in Fagron Australia being operational since November 1, 2012. Fagron Australia will be introducing Fagron's products and concepts to the Australian market.
Latest Developments for Arseus NV
- Arseus sells healthcare specialties and healthcare solutions units; Fagron acquires facilities in Australia, Greece and South Africa
- Arseus closes Medical Universal and Eurotec divestments
- Waterland announces results of private placement of its shares in Arseus
- Waterland announces private placement of its shares in Arseus
Latest Key Developments in Medical
- Share this
- Digg this